Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Obesity is a chronic condition and a key risk factor for a range of other health issues, including type 2 diabetes. In a ...

Altimmune’s lead drug Pemvidutide demonstrates significant progress in obesity and liver health. See why ALT stock is a ...

Swing-state successes in the last midterms gave the party false optimism about 2024.

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

Now, top-line data from the SURMOUNT-1 trial which pitted the drug against placebo in more than 2,500 overweight or obese people without diabetes and with at least one weight-related comorbidity ...